Nine months ended 30 Sep | ||
Key Consolidated Statement of Comprehensive Income Items |
2021 US$ mn (unaudited) |
2020 US$ mn (restated) (unaudited) |
Revenue | 3,305 | 3,200 |
Gross Profit | 645 | 994 |
Share of Profit/(Loss) of a 35%-owned Associate - CTI | (64) | - |
Profit/(Loss) Attributable to Shareholders | (17) | 496 |
Profit Attributable to Shareholders before Biological Assets Fair Value Changes | 110 | 502 |
As at 30 Sep 2021 |
As at 31 Dec 2020 |
|
Key Consolidated Statement of Financial Position Items |
(unaudited) US$ mn |
(audited) US$ mn |
Property, Plant & Equipment | 1,684 | 1,589 |
Investment in Associates | 2,185 | 2,331 |
Total Assets | 6,613 | 6,597 |
Bank and Other Borrowings | 1,384 | 1,136 |
Issued Capital | 253 | 253 |
Shareholders' Equity | 3,248 | 3,548 |
Total Equity | 3,597 | 4,033 |